US20150216213A1 - Liquid nutritional formula for phenylketonuria patients - Google Patents
Liquid nutritional formula for phenylketonuria patients Download PDFInfo
- Publication number
- US20150216213A1 US20150216213A1 US14/616,527 US201514616527A US2015216213A1 US 20150216213 A1 US20150216213 A1 US 20150216213A1 US 201514616527 A US201514616527 A US 201514616527A US 2015216213 A1 US2015216213 A1 US 2015216213A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- nutritional formula
- mcg
- fat
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 52
- 239000007788 liquid Substances 0.000 title claims abstract description 9
- 201000011252 Phenylketonuria Diseases 0.000 title abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 28
- 239000011707 mineral Substances 0.000 claims abstract description 28
- 229940088594 vitamin Drugs 0.000 claims abstract description 24
- 229930003231 vitamin Natural products 0.000 claims abstract description 24
- 235000013343 vitamin Nutrition 0.000 claims abstract description 24
- 239000011782 vitamin Substances 0.000 claims abstract description 24
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 230000000295 complement effect Effects 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 15
- 235000005911 diet Nutrition 0.000 claims abstract description 13
- 230000037213 diet Effects 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 112
- 235000019197 fats Nutrition 0.000 claims description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 26
- 229940024606 amino acid Drugs 0.000 claims description 23
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 235000014633 carbohydrates Nutrition 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 15
- 229960004441 tyrosine Drugs 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 229960002885 histidine Drugs 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- 235000019868 cocoa butter Nutrition 0.000 claims description 5
- 229940110456 cocoa butter Drugs 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- -1 amino acid esters Chemical class 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 2
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 229930195714 L-glutamate Natural products 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 229930182844 L-isoleucine Natural products 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 229930195722 L-methionine Natural products 0.000 claims 2
- 229930182821 L-proline Natural products 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 229930003779 Vitamin B12 Natural products 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 229930003448 Vitamin K Natural products 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229960001231 choline Drugs 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 229910052804 chromium Inorganic materials 0.000 claims 2
- 239000011651 chromium Substances 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 235000013325 dietary fiber Nutrition 0.000 claims 2
- 229960000304 folic acid Drugs 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 2
- 229960004452 methionine Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229910052750 molybdenum Inorganic materials 0.000 claims 2
- 239000011733 molybdenum Substances 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 229940055726 pantothenic acid Drugs 0.000 claims 2
- 235000019161 pantothenic acid Nutrition 0.000 claims 2
- 239000011713 pantothenic acid Substances 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 229960002429 proline Drugs 0.000 claims 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 2
- 235000021003 saturated fats Nutrition 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- 239000011669 selenium Substances 0.000 claims 2
- 229910052711 selenium Inorganic materials 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- 235000019157 thiamine Nutrition 0.000 claims 2
- 239000011721 thiamine Substances 0.000 claims 2
- 229960002898 threonine Drugs 0.000 claims 2
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019163 vitamin B12 Nutrition 0.000 claims 2
- 239000011715 vitamin B12 Substances 0.000 claims 2
- 235000019158 vitamin B6 Nutrition 0.000 claims 2
- 239000011726 vitamin B6 Substances 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 235000019168 vitamin K Nutrition 0.000 claims 2
- 239000011712 vitamin K Substances 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940011671 vitamin b6 Drugs 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 229940046010 vitamin k Drugs 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 235000013928 guanylic acid Nutrition 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 claims 1
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 abstract description 25
- 239000003797 essential amino acid Substances 0.000 abstract description 18
- 235000020776 essential amino acid Nutrition 0.000 abstract description 18
- 235000013361 beverage Nutrition 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 235000019640 taste Nutrition 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract 1
- 201000011296 tyrosinemia Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 83
- 235000013350 formula milk Nutrition 0.000 description 43
- 239000003925 fat Substances 0.000 description 24
- 229940060184 oil ingredients Drugs 0.000 description 21
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 150000003722 vitamin derivatives Chemical class 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 11
- 229920000881 Modified starch Polymers 0.000 description 10
- 239000004368 Modified starch Substances 0.000 description 10
- 235000019426 modified starch Nutrition 0.000 description 10
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 6
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 6
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 5
- 108010067454 caseinomacropeptide Proteins 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 150000001455 metallic ions Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000020616 amino acid formula Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000974 natural food coloring agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Images
Classifications
-
- A23L1/296—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A23L1/3051—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Phenylketonuria is an inherited metabolic error that results in a toxic build-up of phenylalanine (Phe) in the brain and plasma. Infants are screened at birth to determine if they have the genetic defect responsible for PKU. If an infant is diagnosed with the condition, treatment must be initiated immediately, if there is to be a positive outcome. If PKU is undetected or untreated, the nervous system will suffer severe, irreversible damage and the individual will become severely mentally handicapped. Infants diagnosed with PKU must consume a low phenylalanine diet for life to avoid being affected. The original treatment for this disorder was simply to restrict protein in the diet. This fell far short of what was needed. Berry (1980) found that supplementing the diet with valine, isoleucine and leucine provided a method for improving outcome.
- the PKU diets were composed of foods low in protein (and Phe) supplemented with a formula to provide complete nutrition, including amino acids, carbohydrate, fat and essential vitamin and minerals. Because_there were no sources of intact protein that did not contain phenylalanine, purified amino acids were provided in lieu of protein (Brown et al 1992, Acosta et al 2002). Purified amino acid diets have an unpleasant taste because many of the free amino acids provide potent gustatory stimulation. In an effort to minimize the off-flavor notes of amino acid diets, Schweikhardt et al (1995) developed a dragee or capsule. Buist and Prince (1995) formulated a less objectionable mixture of amino acids which had less sensory impact.
- a nutritional formula (also referred to as a nutritional formulation) that has a balanced amino acid profile suitable for therapy for individuals who have phenylketonuria (PKU), including complete, peptide-based, ready-to-drink nutritional formulas, such as shelf-stable, ready-to-drink (liquid), nutritional formulas that have a balanced amino acid profile and are suitable therapy for patients suffering from phenylketonuria.
- PKU phenylketonuria
- the formula is produced under aseptic conditions.
- the formula is canned (placed in containers that are hermetically sealed and sterilized, such as by heat).
- Nutritional formulas that have a balanced amino acid profile suitable for therapy for individuals who have PKU described herein are low in phenylalanine, have low osmolality and have an acceptable taste.
- the nutritional formula comprises: (a) a protein source that comprises (i) caseino-glyco-macropeptide (cGMP) and (ii) complementary essential amino acids which are a mixture of tyrosine, arginine, tryptophan, leucine and histidine and, in combination, provide a balanced amino acid profile that includes an excess of tyrosine; (b) a carbohydrate source, which typically includes non-reducing sugars to minimize/reduce browning potential; (c) a fat (lipid/oil) source; and (d) vitamins and minerals in sufficient quantities to meet the daily requirements for each.
- a protein source that comprises (i) caseino-glyco-macropeptide (cGMP) and (ii) complementary essential amino acids which are a mixture of tyrosine, arginine, tryptophan, leucine and histidine and, in combination, provide a balanced amino acid profile that includes an excess of tyrosine
- a carbohydrate source which typically
- the nutritional formulation typically, but optionally, includes flavors, which can be natural or artificial or a combination of both; coloring agents, which can be natural or artificial or a combination of both; sweetener, which can be natural or artificial or a combination of both; gelling agents, thickening agents, stabilizing agents, sequestrants, emulsifiers or a combination of two or more of gelling agents, thickening agents, stabilizing agents, sequestrants, emulsifiers, each of which can be natural or artificial or a combination of both.
- the protein source provides 10-80% of the energy of the nutritional formula. In some embodiments, the protein source provides 15-35% or 15% to 40% of the energy of the nutritional formula. In some embodiments, the protein source provides 20-80% of the energy of the nutritional formula. In some embodiments, the protein source provides 30-60% of the energy of the nutritional formula. In some embodiments, the protein source provides 40-50% of the energy of the nutritional formula. In some embodiments, the fat source provides 10-80% of the energy of the nutritional formula. In some embodiments, the fat source provides 20-80% of the energy of the nutritional formula. In some embodiments, the fat source provides 30-60% of the energy of the nutritional formula. In some embodiments, the fat source provides 40-50% of the energy of the nutritional formula.
- the carbohydrate source provides 10-100% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 20-80% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 30-60% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 40-50% of the energy of the nutritional formula. In some embodiments, the protein source provides 20-35% of the energy of the nutritional formula, the fat source provides 20% to 30% of the energy of the nutritional formula, and the carbohydrate source provides 40% to 60% of the energy of the nutritional formula.
- the nutritional formula comprises components as shown in Table 1.
- the nutritional formula comprises modified starch, such as octenyl succinate starch or other modified starch that interferes with fat in the formula interacting with protein in the formula, such as by binding of the octenyl moiety of the starch to fat globules; binding of the modified starch to fat interferes (totally or partially) with interaction with proteins by steric hindrance.
- nutritional formulas comprise (a) a protein source that comprises (i) caseino-glyco-macropeptide (cGMP) and (ii) complementary essential amino acids which are a mixture of tyrosine, arginine, tryptophan, leucine and histidine and, in combination, provide a balanced amino acid profile that includes an excess of tyrosine; (b) a carbohydrate source, which typically includes non-reducing sugars to minimize/reduce browning potential; (c) a fat (lipid/oil) source; and (d) vitamins and minerals in amounts and forms to provide, per 100 ml or per 250 ml (8.5 fluid ounces) the components as listed in Table 2, Table 3, Table 4 or Table 5.
- cGMP caseino-glyco-macropeptide
- complementary essential amino acids which are a mixture of tyrosine, arginine, tryptophan, leucine and histidine and, in combination, provide a balanced amino acid profile that includes an excess of
- caseino-glyco-macropeptide (cGMP) in the formulations can be varied, as needed.
- the formulation includes from about 1 g caseino-glyco-macropeptide (cGMP). per 250 mL formulation to about 100 g caseino-glyco-macropeptide (cGMP) per 250 mL formulation.
- the formulation includes from about 5 g caseino-glyco-macropeptide (cGMP) per 250 mL formulation to about 80 g caseino-glyco-macropeptide (cGMP) per 250 mL formulation.
- the formulation includes from about 10 g caseino-glyco-macropeptide per 250 mL formulation to about 70 g caseino-glyco-macropeptide per 250 mL formulation. In some embodiments, the formulation includes from about 20 g caseino-glyco-macropeptide per 250 mL formulation to about 60 g caseino-glyco-macropeptide per 250 mL formulation. In some embodiments, the formulation provides from about 20 g caseino-glyco-macropeptide per 250 mL formulation to about 50 g caseino-glyco-macropeptide per 250 mL formulation.
- each complementary essential amino acid in the formulations can also be varied, as needed.
- the formulation includes from about 0.5 g of each complementary essential amino acid per 250 mL formulation to about 2 g of each complementary essential amino acid per 250 mL formulation.
- the formulation provides from about 1 g of each complementary essential amino acid per 250 mL formulation to about 5 g of each complementary essential amino acid per 250 mL formulation.
- the formulation provides from about 2 g of each complementary essential amino acid per 250 mL formulation to about 10 g of each complementary essential amino acid per 250 mL formulation.
- the formulation provides from about 3 g of each complementary essential amino acid per 250 mL formulation to about 6 g of each complementary essential amino acid per 250 mL formulation.
- the disclosure contemplates the amount of each complementary essential amino acid present in the formulations described herein relative to the amount of protein equivalent (PE) present in the formulations.
- formulation provides from about 1 to about 500 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 10 to about 250 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 20 to about 100 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 50 to about 100 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 10 to about 50 mg per 1 gm of PE of each complementary essential amino acid.
- the amount of carbohydrate source in the formulations described herein can also be varied, as needed.
- the formulation includes from about 1 g carbohydrate source per 250 mL formulation to about 100 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 5 g carbohydrate source per 250 mL formulation to about 80 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 10 g carbohydrate source per 250 mL formulation to about 70 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 20 g carbohydrate source per 250 mL formulation to about 60 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 20 g carbohydrate source per 250 mL formulation to about 50 g carbohydrate source per 250 mL formulation.
- the amount of fat (lipid/oil) source in the formulations described herein can also be varied, as needed.
- the formulation includes from about 1 g fat (lipid/oil) source per 250 mL formulation to about 20 g fat (lipid/oil) source per 250 mL formulation.
- the formulation provides from about 5 g fat (lipid/oil) source per 250 mL formulation to about 15 g fat (lipid/oil) source per 250 mL formulation.
- the formulation provides from about 8 g fat (lipid/oil) source per 250 mL formulation to about 12 g fat (lipid/oil) source per 250 mL formulation.
- each vitamin and each mineral source in the formulations described herein can be varied, as needed.
- the formulation provides from about 0.01 g of each vitamin and each mineral source per 250 mL formulation to about 30 g of each vitamin and each mineral source per 250 mL formulation.
- the formulation provides from about 0.05 g of each vitamin and each mineral source per 250 mL formulation to about 1 g of each vitamin and each mineral source per 250 mL formulation.
- the formulation provides from about 0.5 g of each vitamin and each mineral source per 250 mL formulation to about 5 g of each vitamin and each mineral source per 250 mL formulation.
- the formulation provides from about 2 g of each vitamin and each mineral source per 250 mL formulation to about 10 g of each vitamin and each mineral source per 250 mL formulation. In some embodiments, the formulation provides from about 5 g of each vitamin and each mineral source per 250 mL formulation to about 30 g of each vitamin and each mineral source per 250 mL formulation.
- the formulation described herein is produced, using methods such as those also described herein, in such a manner that tyrosine does not precipitate even when included at levels in excess of its water solubility.
- the formulation is an emulsion in which tyrosine is contained in the lipid fraction.
- the charge interaction is reduced by steric hindrance provided by an octenyl succinate starch.
- the protein/lipid mixture forms a stable thixotropic gel whose viscosity can be precisely adjusted to suspend undissolved components of the mixture (combination). Transition ions in the formulation are ionically bound to reduce their precipitation and contribute to shelf stability.
- the FIGURE is a schematic representation of the method by which nutritional formulas are produced.
- Ready-to-drink, shelf-stable formulae such as beverages pose particular challenges, at least in part because the components essential for complete sustenance components must be incorporated into or combined to produce the nutritional formula in such a way that they remain dissolved, suspended or otherwise retained in the formula (beverage). This is a challenge because each ingredient in the nutritional formula has unique requirements for making it stable.
- Particularly difficult to incorporate is the caseino-glycomacro-peptide, which contains sialic acid attached to an amino acid residue on the chain. This sialic acid reduces the isoelectric point of the peptide as a function of the fraction of sites occupied by sialic acid. Thus, the isoelectric point can change as the peptide is being processed. Peptides are not soluble at or near their isoelectric pH and tend to precipitate or gel. Described herein is a method by which nutritional formulas described are made, with the result that the formula is ready-to-drink and shelf-stable.
- Nutritional formula preparation can be carried out using the method represented schematically in the FIGURE. Kitting of ingredients is carried out as indicated: Kitting of dry ingredients, to produce a dry ingredient mixture is prepared by kitting together dry ingredients without sodium hexametaphosphate (SHMP) or mineral blend; kitting together of SHMP, CuSO 4 , FeSO 4 and, as needed, other minerals; and kitting of ingredients for oil incorporation.
- SHMP sodium hexametaphosphate
- the SHMP and minerals are mixed in water separately.
- Ingredients for oil incorporation are heated and incorporated together. These include tyrosine, OSS, SSL, cocoa butter, vegetable oil and other oil-soluble ingredients. They are subject to high shear and homogenization to produce an emulsion.
- the resulting three combinations are combined with water, as shown in the FIGURE and subjected to the conditions shown, beginning with the step Sequentially Add to High Shear Blender.
- (1) water, GMP, amino acids, vitamins and other dry ingredients are added or introduced into a metered volume of water to produce a first mixture;
- (2) SHMP, minerals and water are kitted together and added to the result of (1);
- the emulsion produced as shown in the FIGURE is incorporated into the result of (1) and (2) and Vitamin C is added to the resulting product, which is subjected to UHT process at about 140° C. for a short time (e.g., 5-6 seconds).
- the resulting formula is stored in an aseptic tank and packaged, such as aseptically.
- the nutritional formula is packaged by canning.
- the dry ingredients include caseino glycomacropeptides (GMP), amino acids, and vitamins.
- SHMP is combined with minerals, such as a metal fortification mixture, which comprises at least one type of metallic ions to produce a SHMP-minerals in water (SHMP-metal mixture).
- metal fortification mixture comprises two or more types of metallic ions.
- the metallic ions is copper (e.g., Cu 2 ⁇ ) and/or iron (e.g., Fe 2+ ).
- the metallic ions are from sources such as CuSO 4 and/or FeSO 4 .
- An emulsion is prepared by combining and heating oil ingredients, which includes tyrosine, modified starch, sodium stearoyl lactylate (SSL), oils such as cocoa butter and vegetable oil, and other oil soluble ingredients.
- the modified starch used herein is an amphiphilic starch, which is hydrophilic and hydrophobic in nature.
- the modified starch is used to bind to fat to prevent the fat from interacting with the proteins by steric hindrance.
- a normally hydrophilic starch is modified to incorporate hydrophobic moieties such as octenyl groups which binds to fats.
- the resulting modified starch has an amphiphilic nature and thus surface active properties which are useful in stabilizing oil/water emulsions.
- the modified starch is octenyl succinate starch (OSS) or another amphiphilic starch.
- OSS octenyl succinate starch
- the hydrophobic octenyl moiety binds the fats in the emulsion assuring that the starch remains attached to the fat globule, preventing the fats from interacting with the proteins by steric hindrance.
- the heated and combined oil ingredients are then added to a mixer, such as a high shear mixer, with water and are homogenized to form an emulsion.
- a mixer such as a high shear mixer
- the oil ingredients are homogenized with water at about 60-80° C. and about 400 psi to about 3000 psi.
- the oil ingredient are homogenized at about 70° C. and about 500 psi to about 2000 psi.
- the mixtures are sequentially added to a blender such as a high shear blender: the dry ingredient mixture is mixed into metered volume of water, the fortified SHMP mixture is added, the emulsion is incorporated, and Vitamin C is added last.
- the vitamin C is sodium ascorbate and/or ascorbic acid.
- UHT ultra-high temperature processing
- the UHT process occurs at 140° C. for about 5 to about 6 seconds.
- the resulting formula is subsequently placed/stored in aseptic tank and then aseptically packaged.
- Dry ingredient mixture was prepared by kitting together the dry ingredients without sodium hexametaphosphate (SHMP), vitamins, or mineral. Table 1 below provides the weight of dry ingredients used.
- the dry ingredients are caseino glycomacropeptides (GMP), amino acids, vitamins, sugar, dextrin, natural flavoring products, natural food coloring, sodium chloride, cellulose gum, carrageenan, and sweeteners.
- GMP caseino glycomacropeptides
- vitamins and minerals are mixed together in water to provide a vitamin and mineral fortification mixture.
- the SHMP with the copper and iron fortification mixture is mixed with the vitamin and mineral fortification mixture, thereby forming a metal/mineral fortified SHMP mixture.
- an emulsion is prepared by combining and heating oil ingredients, which includes L-tyrosine, octenyl succinate modified starch (OSS), sodium stearoyl lactylate (SSL), cocoa butter, vegetable oil.
- oil ingredients which includes L-tyrosine, octenyl succinate modified starch (OSS), sodium stearoyl lactylate (SSL), cocoa butter, vegetable oil.
- the heated and combined oil ingredients are then added to a high shear mixer with water and are homogenized to form an emulsion at about 70° C. and about 500 psi to about 2000 psi.
- the foregoing mixtures are then sequentially added to a blender such as a high shear blender in the following order: the dry ingredient mixture is mixed into metered volume of water, the fortified SHMP mixture is added, the emulsion is incorporated, and Vitamin C (sodium ascorbate and ascorbic acid) is added last.
- Table 1 below provides the amounts of each ingredient used to prepare the formula.
- the combined mixture is subjected to ultra-high temperature processing (UHT) at about 140° C. for about 5 to about 6 seconds
- UHT ultra-high temperature processing
- the resulting formula is subsequently stored in aseptic tank and then aseptically packaged using Prisma Packages.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This application claims the benefit of the filing date of U.S. provisional patent application 61/936,868, filed on Feb. 6, 2014 and U.S. provisional patent application 61/938,653, filed Feb. 11, 2014. The entire teachings and contents of the referenced provisional application are incorporated herein by reference
- Phenylketonuria (PKU) is an inherited metabolic error that results in a toxic build-up of phenylalanine (Phe) in the brain and plasma. Infants are screened at birth to determine if they have the genetic defect responsible for PKU. If an infant is diagnosed with the condition, treatment must be initiated immediately, if there is to be a positive outcome. If PKU is undetected or untreated, the nervous system will suffer severe, irreversible damage and the individual will become severely mentally handicapped. Infants diagnosed with PKU must consume a low phenylalanine diet for life to avoid being affected. The original treatment for this disorder was simply to restrict protein in the diet. This fell far short of what was needed. Berry (1980) found that supplementing the diet with valine, isoleucine and leucine provided a method for improving outcome.
- Subsequently, the PKU diets were composed of foods low in protein (and Phe) supplemented with a formula to provide complete nutrition, including amino acids, carbohydrate, fat and essential vitamin and minerals. Because_there were no sources of intact protein that did not contain phenylalanine, purified amino acids were provided in lieu of protein (Brown et al 1992, Acosta et al 2002). Purified amino acid diets have an unpleasant taste because many of the free amino acids provide potent gustatory stimulation. In an effort to minimize the off-flavor notes of amino acid diets, Schweikhardt et al (1995) developed a dragee or capsule. Buist and Prince (1995) formulated a less objectionable mixture of amino acids which had less sensory impact.
- Compliance is a concern for those with PKU and additional approaches to making palatable and nutritious foods suitable for those with PKU are needed.
- Described herein is a nutritional formula (also referred to as a nutritional formulation) that has a balanced amino acid profile suitable for therapy for individuals who have phenylketonuria (PKU), including complete, peptide-based, ready-to-drink nutritional formulas, such as shelf-stable, ready-to-drink (liquid), nutritional formulas that have a balanced amino acid profile and are suitable therapy for patients suffering from phenylketonuria. In some embodiments, the formula is produced under aseptic conditions. Alternatively, the formula is canned (placed in containers that are hermetically sealed and sterilized, such as by heat). Nutritional formulas that have a balanced amino acid profile suitable for therapy for individuals who have PKU described herein, are low in phenylalanine, have low osmolality and have an acceptable taste.
- The nutritional formula comprises: (a) a protein source that comprises (i) caseino-glyco-macropeptide (cGMP) and (ii) complementary essential amino acids which are a mixture of tyrosine, arginine, tryptophan, leucine and histidine and, in combination, provide a balanced amino acid profile that includes an excess of tyrosine; (b) a carbohydrate source, which typically includes non-reducing sugars to minimize/reduce browning potential; (c) a fat (lipid/oil) source; and (d) vitamins and minerals in sufficient quantities to meet the daily requirements for each. In addition, the nutritional formulation typically, but optionally, includes flavors, which can be natural or artificial or a combination of both; coloring agents, which can be natural or artificial or a combination of both; sweetener, which can be natural or artificial or a combination of both; gelling agents, thickening agents, stabilizing agents, sequestrants, emulsifiers or a combination of two or more of gelling agents, thickening agents, stabilizing agents, sequestrants, emulsifiers, each of which can be natural or artificial or a combination of both.
- In some embodiments, the protein source provides 10-80% of the energy of the nutritional formula. In some embodiments, the protein source provides 15-35% or 15% to 40% of the energy of the nutritional formula. In some embodiments, the protein source provides 20-80% of the energy of the nutritional formula. In some embodiments, the protein source provides 30-60% of the energy of the nutritional formula. In some embodiments, the protein source provides 40-50% of the energy of the nutritional formula. In some embodiments, the fat source provides 10-80% of the energy of the nutritional formula. In some embodiments, the fat source provides 20-80% of the energy of the nutritional formula. In some embodiments, the fat source provides 30-60% of the energy of the nutritional formula. In some embodiments, the fat source provides 40-50% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 10-100% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 20-80% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 30-60% of the energy of the nutritional formula. In some embodiments, the carbohydrate source provides 40-50% of the energy of the nutritional formula. In some embodiments, the protein source provides 20-35% of the energy of the nutritional formula, the fat source provides 20% to 30% of the energy of the nutritional formula, and the carbohydrate source provides 40% to 60% of the energy of the nutritional formula.
- In specific embodiments, the nutritional formula comprises components as shown in Table 1. In specific embodiments, the nutritional formula comprises modified starch, such as octenyl succinate starch or other modified starch that interferes with fat in the formula interacting with protein in the formula, such as by binding of the octenyl moiety of the starch to fat globules; binding of the modified starch to fat interferes (totally or partially) with interaction with proteins by steric hindrance.
- In further specific embodiments, nutritional formulas comprise (a) a protein source that comprises (i) caseino-glyco-macropeptide (cGMP) and (ii) complementary essential amino acids which are a mixture of tyrosine, arginine, tryptophan, leucine and histidine and, in combination, provide a balanced amino acid profile that includes an excess of tyrosine; (b) a carbohydrate source, which typically includes non-reducing sugars to minimize/reduce browning potential; (c) a fat (lipid/oil) source; and (d) vitamins and minerals in amounts and forms to provide, per 100 ml or per 250 ml (8.5 fluid ounces) the components as listed in Table 2, Table 3, Table 4 or Table 5.
- The amount of caseino-glyco-macropeptide (cGMP) in the formulations can be varied, as needed. In some embodiments, the formulation includes from about 1 g caseino-glyco-macropeptide (cGMP). per 250 mL formulation to about 100 g caseino-glyco-macropeptide (cGMP) per 250 mL formulation. In some embodiments, the formulation includes from about 5 g caseino-glyco-macropeptide (cGMP) per 250 mL formulation to about 80 g caseino-glyco-macropeptide (cGMP) per 250 mL formulation. In some embodiments, the formulation includes from about 10 g caseino-glyco-macropeptide per 250 mL formulation to about 70 g caseino-glyco-macropeptide per 250 mL formulation. In some embodiments, the formulation includes from about 20 g caseino-glyco-macropeptide per 250 mL formulation to about 60 g caseino-glyco-macropeptide per 250 mL formulation. In some embodiments, the formulation provides from about 20 g caseino-glyco-macropeptide per 250 mL formulation to about 50 g caseino-glyco-macropeptide per 250 mL formulation.
- The amount of each complementary essential amino acid in the formulations can also be varied, as needed. In some embodiments, the formulation includes from about 0.5 g of each complementary essential amino acid per 250 mL formulation to about 2 g of each complementary essential amino acid per 250 mL formulation. In some embodiments, the formulation provides from about 1 g of each complementary essential amino acid per 250 mL formulation to about 5 g of each complementary essential amino acid per 250 mL formulation. In some embodiments, the formulation provides from about 2 g of each complementary essential amino acid per 250 mL formulation to about 10 g of each complementary essential amino acid per 250 mL formulation. In some embodiments, the formulation provides from about 3 g of each complementary essential amino acid per 250 mL formulation to about 6 g of each complementary essential amino acid per 250 mL formulation.
- In some aspects, the disclosure contemplates the amount of each complementary essential amino acid present in the formulations described herein relative to the amount of protein equivalent (PE) present in the formulations. In some embodiments, formulation provides from about 1 to about 500 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 10 to about 250 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 20 to about 100 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 50 to about 100 mg per 1 gm of PE of each complementary essential amino acid. In some embodiments, formulation provides from about 10 to about 50 mg per 1 gm of PE of each complementary essential amino acid.
- The amount of carbohydrate source in the formulations described herein can also be varied, as needed. In some embodiments, the formulation includes from about 1 g carbohydrate source per 250 mL formulation to about 100 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 5 g carbohydrate source per 250 mL formulation to about 80 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 10 g carbohydrate source per 250 mL formulation to about 70 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 20 g carbohydrate source per 250 mL formulation to about 60 g carbohydrate source per 250 mL formulation. In some embodiments, the formulation provides from about 20 g carbohydrate source per 250 mL formulation to about 50 g carbohydrate source per 250 mL formulation.
- The amount of fat (lipid/oil) source in the formulations described herein can also be varied, as needed. In some embodiments, the formulation includes from about 1 g fat (lipid/oil) source per 250 mL formulation to about 20 g fat (lipid/oil) source per 250 mL formulation. In some embodiments, the formulation provides from about 5 g fat (lipid/oil) source per 250 mL formulation to about 15 g fat (lipid/oil) source per 250 mL formulation. In some embodiments, the formulation provides from about 8 g fat (lipid/oil) source per 250 mL formulation to about 12 g fat (lipid/oil) source per 250 mL formulation.
- The amount of each vitamin and each mineral source in the formulations described herein can be varied, as needed. In some embodiments, the formulation provides from about 0.01 g of each vitamin and each mineral source per 250 mL formulation to about 30 g of each vitamin and each mineral source per 250 mL formulation. In some embodiments, the formulation provides from about 0.05 g of each vitamin and each mineral source per 250 mL formulation to about 1 g of each vitamin and each mineral source per 250 mL formulation. In some embodiments, the formulation provides from about 0.5 g of each vitamin and each mineral source per 250 mL formulation to about 5 g of each vitamin and each mineral source per 250 mL formulation. In some embodiments, the formulation provides from about 2 g of each vitamin and each mineral source per 250 mL formulation to about 10 g of each vitamin and each mineral source per 250 mL formulation. In some embodiments, the formulation provides from about 5 g of each vitamin and each mineral source per 250 mL formulation to about 30 g of each vitamin and each mineral source per 250 mL formulation.
- The formulation described herein is produced, using methods such as those also described herein, in such a manner that tyrosine does not precipitate even when included at levels in excess of its water solubility. The formulation is an emulsion in which tyrosine is contained in the lipid fraction.
- Without wishing to be bound by theory, the charge interaction is reduced by steric hindrance provided by an octenyl succinate starch. The protein/lipid mixture forms a stable thixotropic gel whose viscosity can be precisely adjusted to suspend undissolved components of the mixture (combination). Transition ions in the formulation are ionically bound to reduce their precipitation and contribute to shelf stability.
- The FIGURE is a schematic representation of the method by which nutritional formulas are produced.
- Dietary compliance is the primary issue for PKU patients on amino acid formula, particularly those emerging from childhood. Schuett, V.E.; 1990; (DHHS Publication No HRS-MCH-89-5), reported that more >40% of PKU patients in the US, eight years or older, are not compliant with their diet. The high osmolality, bitterness of amino acids and metallic taste contributed by other components discourage formula consumption. There have been many attempts to improve acceptance of foods and beverages for those with PKU, such as making dry formulae that include caseino glycomacropeptide in combination with amino acids encapsulated to reduce their unpleasant flavor. (Ballevre et al. 2003). Although it might have a pleasant flavor, a powdered formula may not be convenient for a person on the go.
- Ready-to-drink, shelf-stable formulae, such as beverages, pose particular challenges, at least in part because the components essential for complete sustenance components must be incorporated into or combined to produce the nutritional formula in such a way that they remain dissolved, suspended or otherwise retained in the formula (beverage). This is a challenge because each ingredient in the nutritional formula has unique requirements for making it stable. Particularly difficult to incorporate is the caseino-glycomacro-peptide, which contains sialic acid attached to an amino acid residue on the chain. This sialic acid reduces the isoelectric point of the peptide as a function of the fraction of sites occupied by sialic acid. Thus, the isoelectric point can change as the peptide is being processed. Peptides are not soluble at or near their isoelectric pH and tend to precipitate or gel. Described herein is a method by which nutritional formulas described are made, with the result that the formula is ready-to-drink and shelf-stable.
- Nutritional formula preparation can be carried out using the method represented schematically in the FIGURE. Kitting of ingredients is carried out as indicated: Kitting of dry ingredients, to produce a dry ingredient mixture is prepared by kitting together dry ingredients without sodium hexametaphosphate (SHMP) or mineral blend; kitting together of SHMP, CuSO4, FeSO4 and, as needed, other minerals; and kitting of ingredients for oil incorporation. The SHMP and minerals are mixed in water separately. Ingredients for oil incorporation are heated and incorporated together. These include tyrosine, OSS, SSL, cocoa butter, vegetable oil and other oil-soluble ingredients. They are subject to high shear and homogenization to produce an emulsion. The resulting three combinations (see the FIGURE) are combined with water, as shown in the FIGURE and subjected to the conditions shown, beginning with the step Sequentially Add to High Shear Blender. As represented, (1) water, GMP, amino acids, vitamins and other dry ingredients are added or introduced into a metered volume of water to produce a first mixture; (2) SHMP, minerals and water are kitted together and added to the result of (1); (3) the emulsion produced as shown in the FIGURE is incorporated into the result of (1) and (2) and Vitamin C is added to the resulting product, which is subjected to UHT process at about 140° C. for a short time (e.g., 5-6 seconds). The resulting formula is stored in an aseptic tank and packaged, such as aseptically. Alternatively, the nutritional formula is packaged by canning. In some embodiments, the dry ingredients include caseino glycomacropeptides (GMP), amino acids, and vitamins.
- SHMP is combined with minerals, such as a metal fortification mixture, which comprises at least one type of metallic ions to produce a SHMP-minerals in water (SHMP-metal mixture). In some embodiments, metal fortification mixture comprises two or more types of metallic ions. In some embodiments, the metallic ions is copper (e.g., Cu2±) and/or iron (e.g., Fe2+). In some embodiments, the metallic ions are from sources such as CuSO4 and/or FeSO4.
- An emulsion is prepared by combining and heating oil ingredients, which includes tyrosine, modified starch, sodium stearoyl lactylate (SSL), oils such as cocoa butter and vegetable oil, and other oil soluble ingredients. The modified starch used herein is an amphiphilic starch, which is hydrophilic and hydrophobic in nature. The modified starch is used to bind to fat to prevent the fat from interacting with the proteins by steric hindrance. For example, a normally hydrophilic starch is modified to incorporate hydrophobic moieties such as octenyl groups which binds to fats. The resulting modified starch has an amphiphilic nature and thus surface active properties which are useful in stabilizing oil/water emulsions. In some embodiments, the modified starch is octenyl succinate starch (OSS) or another amphiphilic starch. The hydrophobic octenyl moiety binds the fats in the emulsion assuring that the starch remains attached to the fat globule, preventing the fats from interacting with the proteins by steric hindrance.
- The heated and combined oil ingredients are then added to a mixer, such as a high shear mixer, with water and are homogenized to form an emulsion. In some embodiments, the oil ingredients are homogenized with water at about 60-80° C. and about 400 psi to about 3000 psi. In one embodiment, the oil ingredient are homogenized at about 70° C. and about 500 psi to about 2000 psi.
- As shown, the mixtures are sequentially added to a blender such as a high shear blender: the dry ingredient mixture is mixed into metered volume of water, the fortified SHMP mixture is added, the emulsion is incorporated, and Vitamin C is added last. In some embodiments, the vitamin C is sodium ascorbate and/or ascorbic acid. The combined mixture is subjected to ultra-high temperature processing (UHT) at about 130-150° C. for about 4 to about 10 seconds. In one embodiment, the UHT process occurs at 140° C. for about 5 to about 6 seconds. The resulting formula is subsequently placed/stored in aseptic tank and then aseptically packaged.
- Dry ingredient mixture was prepared by kitting together the dry ingredients without sodium hexametaphosphate (SHMP), vitamins, or mineral. Table 1 below provides the weight of dry ingredients used. The dry ingredients are caseino glycomacropeptides (GMP), amino acids, vitamins, sugar, dextrin, natural flavoring products, natural food coloring, sodium chloride, cellulose gum, carrageenan, and sweeteners. In another step, SHMP is combined with a copper and iron fortification mixture. In another step, vitamins and minerals are mixed together in water to provide a vitamin and mineral fortification mixture. Subsequently, the SHMP with the copper and iron fortification mixture is mixed with the vitamin and mineral fortification mixture, thereby forming a metal/mineral fortified SHMP mixture.
- In a separate step, an emulsion is prepared by combining and heating oil ingredients, which includes L-tyrosine, octenyl succinate modified starch (OSS), sodium stearoyl lactylate (SSL), cocoa butter, vegetable oil. The heated and combined oil ingredients are then added to a high shear mixer with water and are homogenized to form an emulsion at about 70° C. and about 500 psi to about 2000 psi.
- The foregoing mixtures are then sequentially added to a blender such as a high shear blender in the following order: the dry ingredient mixture is mixed into metered volume of water, the fortified SHMP mixture is added, the emulsion is incorporated, and Vitamin C (sodium ascorbate and ascorbic acid) is added last. Table 1 below provides the amounts of each ingredient used to prepare the formula. The combined mixture is subjected to ultra-high temperature processing (UHT) at about 140° C. for about 5 to about 6 seconds The resulting formula is subsequently stored in aseptic tank and then aseptically packaged using Prisma Packages.
-
TABLE 1 Glytactin RTD chocolate 12+ Number of Servings: 4 (266.2485 g per serving)/250 ml Weight: 1064.9940 g Quantity Range Units % Weight Total Weight (g) Water 793.05 Gram 74.4652 793.05 Caseino 45.87 30-50 Gram 4.3071 45.87 glycomacropeptides (GMP) copper and iron 0.66 0.462-0.858 Gram 0.062 0.66 fortification Vitamin and mineral 19.68 13.776-25.584 Gram 1.8479 19.68 fortification L-Arginine 6.274 5.0192-7.5288 Gram 0.5891 6.274 L-Histidine 1.398 1.118-1.6956 Gram 0.1313 1.398 L-Leucine 11.2 8.96-13.44 Gram 1.0516 11.2 L-Tryptophan 0.849 0.6792-1.0188 Gram 0.0797 0.849 Sugar 70 59.5-80.5 Gram 6.5728 70 dextrin sweetener 10 8.5-11.5 Gram 0.939 10 Emulsion (see below) 95.07 80.810-109.33 Gram 8.9268 95.07 Natural flavors 3.5 2.975-4.025 Gram 0.3286 3 Natural color 0.5 0.425-0.575 Gram 0.0469 0.5 sodium chloride 0.1 0.085-0.115 Gram 0.0094 0.1 sodium 1.288 0.1-1.5 Gram 0.1209 1.288 hexametaphosphate cellulose gum 4.69 3.0-7.0 Gram 0.4404 4.69 carrageenan 0.373 0.1-0.6 Gram 0.035 0.373 Sweetener, artificial, 0.25 0.2125-0.2875 Gram 0.0235 0.25 Acesulfame-K Sweetener, sucralose, 0.02 0.017-0.023 Gram 0.0019 0.02 granular Vitamin C, sodium 0.152 0.1292-0.1748 Gram 0.0143 0.152 ascorbate Vitamin C, ascorbic acid 0.07 0.0595-0.0805 Gram 0.0066 0.07 Emulsion Number of Servings: 1 (95.071 g per serving) Weight: 95.0710 g Quantity Units % Weight Total Weight (g) L-Tyrosine 5.617 4.383-6.7404 Gram 5.9082 5.617 62-93 mg/gm PE octenyl succinate 11.54 2.0-20 Gram 12.1383 11.54 modified starch Water 57.714 49.0569-66.3711 Gram 60.7062 57.714 Oil, cocoa butter 10 8.5-11.5 Gram 10.5185 10 Oil, canola 10 8.5-11.5 Gram 10.5185 10 sodium stearoyl lactylate 0.2 0.17-0.23 Gram 0.2104 0.2
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/616,527 US9414619B2 (en) | 2014-02-06 | 2015-02-06 | Liquid nutritional formula for phenylketonuria patients |
US15/209,667 US20160316811A1 (en) | 2014-02-06 | 2016-07-13 | Liquid nutritional formula for phenylketonuria patients |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461936868P | 2014-02-06 | 2014-02-06 | |
US201461938653P | 2014-02-11 | 2014-02-11 | |
US14/616,527 US9414619B2 (en) | 2014-02-06 | 2015-02-06 | Liquid nutritional formula for phenylketonuria patients |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/209,667 Continuation US20160316811A1 (en) | 2014-02-06 | 2016-07-13 | Liquid nutritional formula for phenylketonuria patients |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150216213A1 true US20150216213A1 (en) | 2015-08-06 |
US9414619B2 US9414619B2 (en) | 2016-08-16 |
Family
ID=53753708
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/616,527 Active US9414619B2 (en) | 2014-02-06 | 2015-02-06 | Liquid nutritional formula for phenylketonuria patients |
US15/209,667 Abandoned US20160316811A1 (en) | 2014-02-06 | 2016-07-13 | Liquid nutritional formula for phenylketonuria patients |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/209,667 Abandoned US20160316811A1 (en) | 2014-02-06 | 2016-07-13 | Liquid nutritional formula for phenylketonuria patients |
Country Status (2)
Country | Link |
---|---|
US (2) | US9414619B2 (en) |
CA (1) | CA2881076C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016205489A1 (en) * | 2015-06-18 | 2016-12-22 | Cambrooke Therapeutics, Inc. | Formula for management of phenylketonuria |
US20170340694A1 (en) * | 2016-05-26 | 2017-11-30 | Stephen N. Pitcher | Composition for promoting metallothionein production |
EP3355721A4 (en) * | 2015-09-28 | 2019-03-13 | Nestec S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2019081435A1 (en) * | 2017-10-25 | 2019-05-02 | Fresenius Kabi Deutschland Gmbh | All-in-one lyophilized multivitamin emulsion for parenteral application |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102309513B1 (en) | 2011-09-06 | 2021-10-05 | 니코벤처스 트레이딩 리미티드 | Heating smokeable material |
KR102433286B1 (en) | 2011-09-06 | 2022-08-16 | 니코벤처스 트레이딩 리미티드 | Heating smokable material |
GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
CA2881076C (en) * | 2014-02-06 | 2022-06-07 | Cambrooke Foods, Inc. | Liquid nutritional formula for phenylketonuria patients |
US10124036B2 (en) | 2015-06-12 | 2018-11-13 | Cambrooke Therapeutics, Inc. | Liquid nutritional formula for tyrosinemia patients |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587399A (en) * | 1992-12-23 | 1996-12-24 | Abbott Laboratories | Method for preparing medical foods for the nutritional support of infants/toddlers with metabolic diseases |
US20100317562A1 (en) * | 2007-03-23 | 2010-12-16 | Lynn Paolella | Dietary Compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012530067A (en) | 2009-06-12 | 2012-11-29 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | Glycomacropeptide medical food for nutritional management of phenylketonuria and other metabolic disorders |
WO2014171813A1 (en) | 2013-04-17 | 2014-10-23 | N.V. Nutricia | Nutritional composition for improving brain function in phenylketonuria |
CA2881076C (en) * | 2014-02-06 | 2022-06-07 | Cambrooke Foods, Inc. | Liquid nutritional formula for phenylketonuria patients |
US20160366916A1 (en) * | 2015-06-18 | 2016-12-22 | Cambrooke Therapeutics, Inc. | Formula for management of phenylketonuria |
-
2015
- 2015-02-06 CA CA2881076A patent/CA2881076C/en active Active
- 2015-02-06 US US14/616,527 patent/US9414619B2/en active Active
-
2016
- 2016-07-13 US US15/209,667 patent/US20160316811A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587399A (en) * | 1992-12-23 | 1996-12-24 | Abbott Laboratories | Method for preparing medical foods for the nutritional support of infants/toddlers with metabolic diseases |
US20100317562A1 (en) * | 2007-03-23 | 2010-12-16 | Lynn Paolella | Dietary Compositions |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016205489A1 (en) * | 2015-06-18 | 2016-12-22 | Cambrooke Therapeutics, Inc. | Formula for management of phenylketonuria |
EP3355721A4 (en) * | 2015-09-28 | 2019-03-13 | Nestec S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
US20170340694A1 (en) * | 2016-05-26 | 2017-11-30 | Stephen N. Pitcher | Composition for promoting metallothionein production |
US10806768B2 (en) * | 2016-05-26 | 2020-10-20 | Stephen N. Pitcher | Composition for promoting metallothionein production |
WO2019081435A1 (en) * | 2017-10-25 | 2019-05-02 | Fresenius Kabi Deutschland Gmbh | All-in-one lyophilized multivitamin emulsion for parenteral application |
Also Published As
Publication number | Publication date |
---|---|
CA2881076A1 (en) | 2015-08-06 |
CA2881076C (en) | 2022-06-07 |
US20160316811A1 (en) | 2016-11-03 |
US9414619B2 (en) | 2016-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9414619B2 (en) | Liquid nutritional formula for phenylketonuria patients | |
ES2535389T3 (en) | Substantially clear nutritional fluids comprising HMB of calcium and soluble proteins | |
EP1077616B1 (en) | Nutritional product for a person having renal failure | |
JP5734314B2 (en) | Nutritional emulsion containing calcium HMB and soluble protein | |
US20130337144A1 (en) | Nutritional products comprising calcium hmb and conjugated linoleic acid | |
JP7165583B2 (en) | High Calorie, High Protein Nutritional Formula with Collagen | |
JP2013517808A (en) | Nutritional emulsion containing calcium HMB | |
CN109982585B (en) | Nutritional composition for use in therapy of patients suffering from sarcopenia and/or frailty or pre-sarcopenia and/or pre-frailty patients | |
EP2986163B1 (en) | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein | |
US9889162B2 (en) | Prophylactic use for prevention of infections | |
US20160366916A1 (en) | Formula for management of phenylketonuria | |
CN104379172B (en) | Nutritional composition | |
WO2016029074A1 (en) | Nutritional beverage containing rice protein | |
US10124036B2 (en) | Liquid nutritional formula for tyrosinemia patients | |
Fomon et al. | Isolated soy protein in infant feeding | |
WO2015089007A1 (en) | Nutritional compositions containing brown rice protein | |
CA2894333C (en) | Liquid nutritional formula for tyrosinemia patients | |
WO2017116805A1 (en) | Nutritional products comprising lutein | |
US11058657B2 (en) | Nutritional composition for use in therapy of cancer patients | |
US20110274678A1 (en) | Beverage | |
JP2023069186A (en) | Nutritive composition, manufacturing method of nutritive composition, and evaluation method of bioavailability of copper in nutritive composition | |
WO2017116807A1 (en) | Liquid nutritional products comprising lutein with low off-color development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CAMBROOKE THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIZER, CHARLES E.;ALEA, LEAH;OLSON, KURT;SIGNING DATES FROM 20150317 TO 20160303;REEL/FRAME:037967/0560 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: AJINOMOTO CAMBROOKE, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:CAMBROOKE THERAPEUTICS, INC.;REEL/FRAME:051928/0519 Effective date: 20190401 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: SURCHARGE FOR LATE PAYMENT, LARGE ENTITY (ORIGINAL EVENT CODE: M1554); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |